Malaria vaccine - Apovia

Drug Profile

Malaria vaccine - Apovia

Alternative Names: ICC 1132; MalariVax™

Latest Information Update: 22 Nov 2006

Price : $50

At a glance

  • Originator Apovia (CEASED)
  • Developer Malaria Vaccine Initiative
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 18 Feb 2005 A clinical study has been added to the Parasitic infections immunogenicity section
  • 16 Dec 2003 Data presented at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH-2003) have been added to the Parasitic Infections immunogenicity section
  • 03 Dec 2003 A phase I trial has been completed for Malaria in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top